Recipharm has signed a partnership agreement with Follicum AB to formulate and produce the drug candidate FOL-005 for a clinical trial. Recipharm will also develop and validate the analytical methods required. In preclinical studies, FOL-005 has both stimulated and inhibited hair growth effectively even at low doses.
 
“Preparations for the clinical study are well under way, and we have now established ties with partners that we feel confident in. Recipharm is successful in its field and has a strong track record. We look forward to the finished product, which is expected to be ready at the end of the year, in time for the launch of the clinical study,” says Jan Alenfall, chief executive officer of Follicum.
 
“We have extensive experience in the development of pharmaceuticals for clinical trials and are very excited to be able to contribute to the development of this product,” said Maria Lundberg, general manager of Recipharm in Solna.